title: Treatment of pulmonary hypertension.
abstract: Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PAH is considered a life-threatening condition unless treated. This article provides a comprehensive review of controlled and uncontrolled trials to define the risk-benefit for different therapeutic options of this clinical disorder. Relevant published articles were identified through searches of the National Center for Biotechnology PubMed database. All therapeutic measures for PAH were discussed. Six drugs have been approved in the United States for the treatment of PAH. Extensive medical advancement has been achieved in treatment of PAH. However, none of the approved therapies have shown ability to cure the disease. New research should be performed to develop promising new therapies.
authors.affiliation: Essen Medical Associates, Bronx, NY, USA.
authors.forename: Rajendrakumar
authors.initials: R
authors.lastname: Patel
authors.forename: Wilbert S
authors.initials: WS
authors.lastname: Aronow
authors.forename: Laxeshkumar
authors.initials: L
authors.lastname: Patel
authors.forename: Kaushang
authors.initials: K
authors.lastname: Gandhi
authors.forename: Harit
authors.initials: H
authors.lastname: Desai
authors.forename: Dhiraj
authors.initials: D
authors.lastname: Kaul
authors.forename: Sumir P
authors.initials: SP
authors.lastname: Sahgal
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000959:Antihypertensive Agents